Nuvalent, Inc.NUVLEarnings & Financial Report
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted precision therapies for cancer patients. The firm designs novel molecules to address unmet needs in solid tumor treatment, targeting specific genetic mutations that drive cancer growth, with multiple oncology pipeline candidates advancing through clinical development for global markets.
NUVL Q3 FY2024 Key Financial Metrics
Revenue
$8.7M
Gross Profit
N/A
Operating Profit
$-76.3M
Net Profit
$-84.3M
Gross Margin
N/A
Operating Margin
-877.4%
Net Margin
-969.5%
YoY Growth
74.0%
EPS
$-1.28
Nuvalent, Inc. Q3 FY2024 Financial Summary
Nuvalent, Inc. reported revenue of $8.7M (up 74.0% YoY) for Q3 FY2024, with a net profit of $-84.3M (down 150.7% YoY) (-969.5% margin).
Key Financial Metrics
| Total Revenue | $8.7M |
|---|---|
| Net Profit | $-84.3M |
| Gross Margin | N/A |
| Operating Margin | -877.4% |
| Report Period | Q3 FY2024 |
Nuvalent, Inc. Quarterly Revenue & Net Profit History
Nuvalent, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $8.7M | +74.0% | $-84.3M | -969.5% |
| Q2 FY2024 | $8.1M | +58.8% | $-57.2M | -705.8% |
| Q1 FY2024 | $8.5M | +70.0% | $-44.5M | -523.3% |
| Q3 FY2023 | $5.0M | — | $-33.6M | -672.9% |
| Q2 FY2023 | $5.1M | — | $-29.1M | -570.4% |
| Q1 FY2023 | $5.0M | — | $-25.2M | -503.8% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $5.0M | $5.1M | $5.0M | $8.5M | $8.1M | $8.7M |
| YoY Growth | N/A | N/A | N/A | 70.0% | 58.8% | 74.0% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Assets | $461.0M | $441.9M | $425.1M | $708.5M | $675.2M | $1.19B |
| Liabilities | $17.0M | $20.8M | $29.1M | $33.4M | $38.2M | $67.7M |
| Equity | $444.0M | $421.2M | $396.0M | $675.0M | $637.0M | $1.12B |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Operating CF | $-24.4M | $-22.1M | $-23.0M | $-36.1M | $-41.2M | $-45.8M |